Anika Therapeutics Inc (ANIK)
27.59
0.00 (0.00%)
USD |
NASDAQ |
May 03, 16:00
27.74
+0.15
(+0.54%)
After-Hours: 20:00
Anika Therapeutics Research and Development Expense (Quarterly): 7.585M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 7.585M |
| September 30, 2023 | 7.791M |
| June 30, 2023 | 8.914M |
| March 31, 2023 | 8.40M |
| December 31, 2022 | 7.749M |
| September 30, 2022 | 7.301M |
| June 30, 2022 | 6.975M |
| March 31, 2022 | 6.157M |
| December 31, 2021 | 6.00M |
| September 30, 2021 | 7.673M |
| June 30, 2021 | 7.293M |
| March 31, 2021 | 6.361M |
| December 31, 2020 | 7.632M |
| September 30, 2020 | 5.217M |
| June 30, 2020 | 4.532M |
| March 31, 2020 | 6.05M |
| December 31, 2019 | 4.084M |
| September 30, 2019 | 4.158M |
| June 30, 2019 | 4.165M |
| March 31, 2019 | 4.258M |
| December 31, 2018 | 4.064M |
| September 30, 2018 | 4.232M |
| June 30, 2018 | 4.733M |
| March 31, 2018 | 5.161M |
| December 31, 2017 | 4.266M |
| Date | Value |
|---|---|
| September 30, 2017 | 5.842M |
| June 30, 2017 | 4.449M |
| March 31, 2017 | 4.23M |
| December 31, 2016 | 2.959M |
| September 30, 2016 | 2.822M |
| June 30, 2016 | 2.792M |
| March 31, 2016 | 2.159M |
| December 31, 2015 | 3.016M |
| September 30, 2015 | 2.061M |
| June 30, 2015 | 1.812M |
| March 31, 2015 | 2.098M |
| December 31, 2014 | 1.983M |
| September 30, 2014 | 2.000M |
| June 30, 2014 | 1.873M |
| March 31, 2014 | 2.288M |
| December 31, 2013 | 2.03M |
| September 30, 2013 | 1.618M |
| June 30, 2013 | 1.829M |
| March 31, 2013 | 1.583M |
| December 31, 2012 | 1.340M |
| September 30, 2012 | 1.217M |
| June 30, 2012 | 1.298M |
| March 31, 2012 | 1.533M |
| December 31, 2011 | 1.531M |
| September 30, 2011 | 1.531M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
4.084M
Minimum
Dec 2019
8.914M
Maximum
Jun 2023
6.528M
Average
6.975M
Median
Jun 2022
Research and Development Expense (Quarterly) Benchmarks
| The Cooper Companies Inc | 39.50M |
| Staar Surgical Co | 10.87M |
| OrthoPediatrics Corp | 2.747M |
| NexGel Inc | 0.013M |
| Innovative Eyewear Inc | 0.1208M |